Global Renal Disease research

Renal Disease Comprehensive Study by Disease Type (Chronic Kidney Disease, Kidney Stones, Glomerulonephritis, Polycystic Kidney Disease, Urinary Tract Infections), Treatment (Medication, Dialysis (Haemodialysis, Peritoneal Dialysis), Surgery (Kidney Transplant)), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Symptoms (Loss of Appetite., Sleep Problems., Decreased Mental Sharpness., Muscle Cramps, Others), End User (Hospitals, Homecare, Specialty Clinics) Players and Region - Global Market Outlook to 2028

Renal Disease Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Renal Disease Market Overview:
Renal disease is a condition in which the kidneys stop working and are not able to remove waste and extra water from the blood or keep body chemicals in balance. The renal disease damages the nephron, unable for the kidney to function to remove the waste product from the body. The disease can cause other severe problems such as hypertension, kidney failure, brain aneurysm, and chronic pain. Other symptoms include blood in urine, kidney stones, urinary tract or kidney infections, and back or side pain. It may develop over many years and lead to renal disease. It has become a massive public health issue. An increase in the incidence of diabetes, high blood pressure, and hypertension in patients are driving factors for the renal disease market.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Rising Government Support for the Quality Generic Medicines.

Market Growth Drivers:
Increased Incidence of Kidney Diseases, Huge Demand for Pharmacotherapy and Technological Advancements in Dialysis and Surgeries

Challenges:
Shortage in Availability of Kidneys for Transplants, Need For Continuous Improvement in Treatments Offering and Weak Health System and Lack of Infrastructure

Restraints:
Global Shortage of Donors, Lack of Awareness and Other Misconceptions about Renal Disease and Abuse of Over-The-Counter Medicines

Opportunities:
Treatment Advancement Such As - Kidneys from Non-Human Mammals, Creating a Bioartificial Kidney as a Permanent Solution to Kidney Failure and Growing Awareness about Machine Learning and Artificial Intelligence Algorithms to Classify Patients into Homogenous Subclasses

Competitive Landscape:
Renal Disease Market is a fragmented market due to the presence of various players. The players are focusing on developing technological advancements and therapeutic advancement for the betterment of public health related to renal diseases. Further growing demand for awareness about machine learning and artificial intelligence will contribute to increasing the market presence. The companies are also planning strategic activities such as product launches, collaborations, mergers, and acquisitions to sustain in the market and maintain their competitive edge.
Some of the key players profiled in the report are AM-Pharma (Netherlands), Pfizer Inc. (United States), GlaxoSmithKline (United Kingdom), Atlentis Therapeutics (Switzerland), Calyxo (United States), Chinook Therapeutics (Canada), CinCor (India), Early is Good (United States), Federation Bio (United States), Renalytix (United Kingdom), Frenova Renal Research (United States), Goldfinch Bio (Cambridge), Kibow Biotech (United States), Liminal BioSciences (Canada) and Renalytix (United Kingdom). Additionally, following companies can also be profiled that are part of our coverage like The Rogosin Institute (United States), Vera Therapeutics (United States), ProKidney (United States) and Osprey Medical (United States). Considering Market by Disease Type, the sub-segment i.e. Chronic Kidney Disease will boost the Renal Disease market. Considering Market by Treatment, the sub-segment i.e. Medication will boost the Renal Disease market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Renal Disease market. Considering Market by Symptoms, the sub-segment i.e. Loss of Appetite. will boost the Renal Disease market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Renal Disease market.

Latest Market Insights:
On October 2022, Pfizer acquired Biohaven Pharmaceuticals, the maker of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults., and On November 2021, GSK announced positive Phase III efficacy and safety data for daprodustat in patients with anemia due to chronic kidney disease. The positive primary efficacy and safety results confirm the potential for daprodustat to be a new oral treatment for patients with anemia due to chronic kidney disease (CKD) in both non-dialysis and dialysis settings. Daprodustat was developed based on the unique Nobel Prize-winning science that demonstrated how cells sense and adapts to oxygen availability.

On January 2023, Renalytix launched a consortium focused on advancing biomarker-based tests for predicting responses to existing drugs used by chronic kidney disease (CKD) patients.

What Can be Explored with the Renal Disease Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Renal Disease Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Renal Disease
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Renal Disease market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Renal Disease market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Disease Type
  • Chronic Kidney Disease
  • Kidney Stones
  • Glomerulonephritis
  • Polycystic Kidney Disease
  • Urinary Tract Infections

By Treatment
  • Medication
  • Dialysis (Haemodialysis, Peritoneal Dialysis)
  • Surgery (Kidney Transplant)

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Symptoms
  • Loss of Appetite.
  • Sleep Problems.
  • Decreased Mental Sharpness.
  • Muscle Cramps
  • Others

By End User
  • Hospitals
  • Homecare
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Incidence of Kidney Diseases
      • 3.2.2. Huge Demand for Pharmacotherapy
      • 3.2.3. Technological Advancements in Dialysis and Surgeries
    • 3.3. Market Challenges
      • 3.3.1. Shortage in Availability of Kidneys for Transplants
      • 3.3.2. Need For Continuous Improvement in Treatments Offering
      • 3.3.3. Weak Health System and Lack of Infrastructure
    • 3.4. Market Trends
      • 3.4.1. Rising Government Support for the Quality Generic Medicines.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Renal Disease, by Disease Type, Treatment, Distribution Channel, Symptoms, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Renal Disease (Value)
      • 5.2.1. Global Renal Disease by: Disease Type (Value)
        • 5.2.1.1. Chronic Kidney Disease
        • 5.2.1.2. Kidney Stones
        • 5.2.1.3. Glomerulonephritis
        • 5.2.1.4. Polycystic Kidney Disease
        • 5.2.1.5. Urinary Tract Infections
      • 5.2.2. Global Renal Disease by: Treatment (Value)
        • 5.2.2.1. Medication
        • 5.2.2.2. Dialysis (Haemodialysis, Peritoneal Dialysis)
        • 5.2.2.3. Surgery (Kidney Transplant)
      • 5.2.3. Global Renal Disease by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Online Pharmacy
        • 5.2.3.3. Retail Pharmacy
      • 5.2.4. Global Renal Disease by: Symptoms (Value)
        • 5.2.4.1. Loss of Appetite.
        • 5.2.4.2. Sleep Problems.
        • 5.2.4.3. Decreased Mental Sharpness.
        • 5.2.4.4. Muscle Cramps
        • 5.2.4.5. Others
      • 5.2.5. Global Renal Disease by: End User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Homecare
        • 5.2.5.3. Specialty Clinics
      • 5.2.6. Global Renal Disease Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Renal Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AM-Pharma (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Atlentis Therapeutics (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Calyxo (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Chinook Therapeutics (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CinCor (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Early is Good (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Federation Bio (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Renalytix (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Frenova Renal Research (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Goldfinch Bio (Cambridge)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Kibow Biotech (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Liminal BioSciences (Canada)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Renalytix (United Kingdom)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Renal Disease Sale, by Disease Type, Treatment, Distribution Channel, Symptoms, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Renal Disease (Value)
      • 7.2.1. Global Renal Disease by: Disease Type (Value)
        • 7.2.1.1. Chronic Kidney Disease
        • 7.2.1.2. Kidney Stones
        • 7.2.1.3. Glomerulonephritis
        • 7.2.1.4. Polycystic Kidney Disease
        • 7.2.1.5. Urinary Tract Infections
      • 7.2.2. Global Renal Disease by: Treatment (Value)
        • 7.2.2.1. Medication
        • 7.2.2.2. Dialysis (Haemodialysis, Peritoneal Dialysis)
        • 7.2.2.3. Surgery (Kidney Transplant)
      • 7.2.3. Global Renal Disease by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Online Pharmacy
        • 7.2.3.3. Retail Pharmacy
      • 7.2.4. Global Renal Disease by: Symptoms (Value)
        • 7.2.4.1. Loss of Appetite.
        • 7.2.4.2. Sleep Problems.
        • 7.2.4.3. Decreased Mental Sharpness.
        • 7.2.4.4. Muscle Cramps
        • 7.2.4.5. Others
      • 7.2.5. Global Renal Disease by: End User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Homecare
        • 7.2.5.3. Specialty Clinics
      • 7.2.6. Global Renal Disease Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Renal Disease: by Disease Type(USD Million)
  • Table 2. Renal Disease Chronic Kidney Disease , by Region USD Million (2017-2022)
  • Table 3. Renal Disease Kidney Stones , by Region USD Million (2017-2022)
  • Table 4. Renal Disease Glomerulonephritis , by Region USD Million (2017-2022)
  • Table 5. Renal Disease Polycystic Kidney Disease , by Region USD Million (2017-2022)
  • Table 6. Renal Disease Urinary Tract Infections , by Region USD Million (2017-2022)
  • Table 7. Renal Disease: by Treatment(USD Million)
  • Table 8. Renal Disease Medication , by Region USD Million (2017-2022)
  • Table 9. Renal Disease Dialysis (Haemodialysis, Peritoneal Dialysis) , by Region USD Million (2017-2022)
  • Table 10. Renal Disease Surgery (Kidney Transplant) , by Region USD Million (2017-2022)
  • Table 11. Renal Disease: by Distribution Channel(USD Million)
  • Table 12. Renal Disease Hospital Pharmacy , by Region USD Million (2017-2022)
  • Table 13. Renal Disease Online Pharmacy , by Region USD Million (2017-2022)
  • Table 14. Renal Disease Retail Pharmacy , by Region USD Million (2017-2022)
  • Table 15. Renal Disease: by Symptoms(USD Million)
  • Table 16. Renal Disease Loss of Appetite. , by Region USD Million (2017-2022)
  • Table 17. Renal Disease Sleep Problems. , by Region USD Million (2017-2022)
  • Table 18. Renal Disease Decreased Mental Sharpness. , by Region USD Million (2017-2022)
  • Table 19. Renal Disease Muscle Cramps , by Region USD Million (2017-2022)
  • Table 20. Renal Disease Others , by Region USD Million (2017-2022)
  • Table 21. Renal Disease: by End User(USD Million)
  • Table 22. Renal Disease Hospitals , by Region USD Million (2017-2022)
  • Table 23. Renal Disease Homecare , by Region USD Million (2017-2022)
  • Table 24. Renal Disease Specialty Clinics , by Region USD Million (2017-2022)
  • Table 25. South America Renal Disease, by Country USD Million (2017-2022)
  • Table 26. South America Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 27. South America Renal Disease, by Treatment USD Million (2017-2022)
  • Table 28. South America Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 29. South America Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 30. South America Renal Disease, by End User USD Million (2017-2022)
  • Table 31. Brazil Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 32. Brazil Renal Disease, by Treatment USD Million (2017-2022)
  • Table 33. Brazil Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 34. Brazil Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 35. Brazil Renal Disease, by End User USD Million (2017-2022)
  • Table 36. Argentina Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 37. Argentina Renal Disease, by Treatment USD Million (2017-2022)
  • Table 38. Argentina Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 39. Argentina Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 40. Argentina Renal Disease, by End User USD Million (2017-2022)
  • Table 41. Rest of South America Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 42. Rest of South America Renal Disease, by Treatment USD Million (2017-2022)
  • Table 43. Rest of South America Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 44. Rest of South America Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 45. Rest of South America Renal Disease, by End User USD Million (2017-2022)
  • Table 46. Asia Pacific Renal Disease, by Country USD Million (2017-2022)
  • Table 47. Asia Pacific Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 48. Asia Pacific Renal Disease, by Treatment USD Million (2017-2022)
  • Table 49. Asia Pacific Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 50. Asia Pacific Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 51. Asia Pacific Renal Disease, by End User USD Million (2017-2022)
  • Table 52. China Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 53. China Renal Disease, by Treatment USD Million (2017-2022)
  • Table 54. China Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 55. China Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 56. China Renal Disease, by End User USD Million (2017-2022)
  • Table 57. Japan Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 58. Japan Renal Disease, by Treatment USD Million (2017-2022)
  • Table 59. Japan Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 60. Japan Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 61. Japan Renal Disease, by End User USD Million (2017-2022)
  • Table 62. India Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 63. India Renal Disease, by Treatment USD Million (2017-2022)
  • Table 64. India Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 65. India Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 66. India Renal Disease, by End User USD Million (2017-2022)
  • Table 67. South Korea Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 68. South Korea Renal Disease, by Treatment USD Million (2017-2022)
  • Table 69. South Korea Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 70. South Korea Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 71. South Korea Renal Disease, by End User USD Million (2017-2022)
  • Table 72. Taiwan Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 73. Taiwan Renal Disease, by Treatment USD Million (2017-2022)
  • Table 74. Taiwan Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 75. Taiwan Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 76. Taiwan Renal Disease, by End User USD Million (2017-2022)
  • Table 77. Australia Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 78. Australia Renal Disease, by Treatment USD Million (2017-2022)
  • Table 79. Australia Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 80. Australia Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 81. Australia Renal Disease, by End User USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Renal Disease, by Treatment USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Renal Disease, by End User USD Million (2017-2022)
  • Table 87. Europe Renal Disease, by Country USD Million (2017-2022)
  • Table 88. Europe Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 89. Europe Renal Disease, by Treatment USD Million (2017-2022)
  • Table 90. Europe Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 91. Europe Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 92. Europe Renal Disease, by End User USD Million (2017-2022)
  • Table 93. Germany Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 94. Germany Renal Disease, by Treatment USD Million (2017-2022)
  • Table 95. Germany Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 96. Germany Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 97. Germany Renal Disease, by End User USD Million (2017-2022)
  • Table 98. France Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 99. France Renal Disease, by Treatment USD Million (2017-2022)
  • Table 100. France Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 101. France Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 102. France Renal Disease, by End User USD Million (2017-2022)
  • Table 103. Italy Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 104. Italy Renal Disease, by Treatment USD Million (2017-2022)
  • Table 105. Italy Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 106. Italy Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 107. Italy Renal Disease, by End User USD Million (2017-2022)
  • Table 108. United Kingdom Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 109. United Kingdom Renal Disease, by Treatment USD Million (2017-2022)
  • Table 110. United Kingdom Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 111. United Kingdom Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 112. United Kingdom Renal Disease, by End User USD Million (2017-2022)
  • Table 113. Netherlands Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 114. Netherlands Renal Disease, by Treatment USD Million (2017-2022)
  • Table 115. Netherlands Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 116. Netherlands Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 117. Netherlands Renal Disease, by End User USD Million (2017-2022)
  • Table 118. Rest of Europe Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 119. Rest of Europe Renal Disease, by Treatment USD Million (2017-2022)
  • Table 120. Rest of Europe Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 121. Rest of Europe Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 122. Rest of Europe Renal Disease, by End User USD Million (2017-2022)
  • Table 123. MEA Renal Disease, by Country USD Million (2017-2022)
  • Table 124. MEA Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 125. MEA Renal Disease, by Treatment USD Million (2017-2022)
  • Table 126. MEA Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 127. MEA Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 128. MEA Renal Disease, by End User USD Million (2017-2022)
  • Table 129. Middle East Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 130. Middle East Renal Disease, by Treatment USD Million (2017-2022)
  • Table 131. Middle East Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 132. Middle East Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 133. Middle East Renal Disease, by End User USD Million (2017-2022)
  • Table 134. Africa Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 135. Africa Renal Disease, by Treatment USD Million (2017-2022)
  • Table 136. Africa Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 137. Africa Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 138. Africa Renal Disease, by End User USD Million (2017-2022)
  • Table 139. North America Renal Disease, by Country USD Million (2017-2022)
  • Table 140. North America Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 141. North America Renal Disease, by Treatment USD Million (2017-2022)
  • Table 142. North America Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 143. North America Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 144. North America Renal Disease, by End User USD Million (2017-2022)
  • Table 145. United States Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 146. United States Renal Disease, by Treatment USD Million (2017-2022)
  • Table 147. United States Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 148. United States Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 149. United States Renal Disease, by End User USD Million (2017-2022)
  • Table 150. Canada Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 151. Canada Renal Disease, by Treatment USD Million (2017-2022)
  • Table 152. Canada Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 153. Canada Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 154. Canada Renal Disease, by End User USD Million (2017-2022)
  • Table 155. Mexico Renal Disease, by Disease Type USD Million (2017-2022)
  • Table 156. Mexico Renal Disease, by Treatment USD Million (2017-2022)
  • Table 157. Mexico Renal Disease, by Distribution Channel USD Million (2017-2022)
  • Table 158. Mexico Renal Disease, by Symptoms USD Million (2017-2022)
  • Table 159. Mexico Renal Disease, by End User USD Million (2017-2022)
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Renal Disease: by Disease Type(USD Million)
  • Table 176. Renal Disease Chronic Kidney Disease , by Region USD Million (2023-2028)
  • Table 177. Renal Disease Kidney Stones , by Region USD Million (2023-2028)
  • Table 178. Renal Disease Glomerulonephritis , by Region USD Million (2023-2028)
  • Table 179. Renal Disease Polycystic Kidney Disease , by Region USD Million (2023-2028)
  • Table 180. Renal Disease Urinary Tract Infections , by Region USD Million (2023-2028)
  • Table 181. Renal Disease: by Treatment(USD Million)
  • Table 182. Renal Disease Medication , by Region USD Million (2023-2028)
  • Table 183. Renal Disease Dialysis (Haemodialysis, Peritoneal Dialysis) , by Region USD Million (2023-2028)
  • Table 184. Renal Disease Surgery (Kidney Transplant) , by Region USD Million (2023-2028)
  • Table 185. Renal Disease: by Distribution Channel(USD Million)
  • Table 186. Renal Disease Hospital Pharmacy , by Region USD Million (2023-2028)
  • Table 187. Renal Disease Online Pharmacy , by Region USD Million (2023-2028)
  • Table 188. Renal Disease Retail Pharmacy , by Region USD Million (2023-2028)
  • Table 189. Renal Disease: by Symptoms(USD Million)
  • Table 190. Renal Disease Loss of Appetite. , by Region USD Million (2023-2028)
  • Table 191. Renal Disease Sleep Problems. , by Region USD Million (2023-2028)
  • Table 192. Renal Disease Decreased Mental Sharpness. , by Region USD Million (2023-2028)
  • Table 193. Renal Disease Muscle Cramps , by Region USD Million (2023-2028)
  • Table 194. Renal Disease Others , by Region USD Million (2023-2028)
  • Table 195. Renal Disease: by End User(USD Million)
  • Table 196. Renal Disease Hospitals , by Region USD Million (2023-2028)
  • Table 197. Renal Disease Homecare , by Region USD Million (2023-2028)
  • Table 198. Renal Disease Specialty Clinics , by Region USD Million (2023-2028)
  • Table 199. South America Renal Disease, by Country USD Million (2023-2028)
  • Table 200. South America Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 201. South America Renal Disease, by Treatment USD Million (2023-2028)
  • Table 202. South America Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 203. South America Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 204. South America Renal Disease, by End User USD Million (2023-2028)
  • Table 205. Brazil Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 206. Brazil Renal Disease, by Treatment USD Million (2023-2028)
  • Table 207. Brazil Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 208. Brazil Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 209. Brazil Renal Disease, by End User USD Million (2023-2028)
  • Table 210. Argentina Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 211. Argentina Renal Disease, by Treatment USD Million (2023-2028)
  • Table 212. Argentina Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 213. Argentina Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 214. Argentina Renal Disease, by End User USD Million (2023-2028)
  • Table 215. Rest of South America Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 216. Rest of South America Renal Disease, by Treatment USD Million (2023-2028)
  • Table 217. Rest of South America Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 218. Rest of South America Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 219. Rest of South America Renal Disease, by End User USD Million (2023-2028)
  • Table 220. Asia Pacific Renal Disease, by Country USD Million (2023-2028)
  • Table 221. Asia Pacific Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 222. Asia Pacific Renal Disease, by Treatment USD Million (2023-2028)
  • Table 223. Asia Pacific Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 224. Asia Pacific Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 225. Asia Pacific Renal Disease, by End User USD Million (2023-2028)
  • Table 226. China Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 227. China Renal Disease, by Treatment USD Million (2023-2028)
  • Table 228. China Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 229. China Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 230. China Renal Disease, by End User USD Million (2023-2028)
  • Table 231. Japan Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 232. Japan Renal Disease, by Treatment USD Million (2023-2028)
  • Table 233. Japan Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 234. Japan Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 235. Japan Renal Disease, by End User USD Million (2023-2028)
  • Table 236. India Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 237. India Renal Disease, by Treatment USD Million (2023-2028)
  • Table 238. India Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 239. India Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 240. India Renal Disease, by End User USD Million (2023-2028)
  • Table 241. South Korea Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 242. South Korea Renal Disease, by Treatment USD Million (2023-2028)
  • Table 243. South Korea Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 244. South Korea Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 245. South Korea Renal Disease, by End User USD Million (2023-2028)
  • Table 246. Taiwan Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 247. Taiwan Renal Disease, by Treatment USD Million (2023-2028)
  • Table 248. Taiwan Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 249. Taiwan Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 250. Taiwan Renal Disease, by End User USD Million (2023-2028)
  • Table 251. Australia Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 252. Australia Renal Disease, by Treatment USD Million (2023-2028)
  • Table 253. Australia Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 254. Australia Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 255. Australia Renal Disease, by End User USD Million (2023-2028)
  • Table 256. Rest of Asia-Pacific Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 257. Rest of Asia-Pacific Renal Disease, by Treatment USD Million (2023-2028)
  • Table 258. Rest of Asia-Pacific Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 259. Rest of Asia-Pacific Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 260. Rest of Asia-Pacific Renal Disease, by End User USD Million (2023-2028)
  • Table 261. Europe Renal Disease, by Country USD Million (2023-2028)
  • Table 262. Europe Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 263. Europe Renal Disease, by Treatment USD Million (2023-2028)
  • Table 264. Europe Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 265. Europe Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 266. Europe Renal Disease, by End User USD Million (2023-2028)
  • Table 267. Germany Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 268. Germany Renal Disease, by Treatment USD Million (2023-2028)
  • Table 269. Germany Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 270. Germany Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 271. Germany Renal Disease, by End User USD Million (2023-2028)
  • Table 272. France Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 273. France Renal Disease, by Treatment USD Million (2023-2028)
  • Table 274. France Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 275. France Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 276. France Renal Disease, by End User USD Million (2023-2028)
  • Table 277. Italy Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 278. Italy Renal Disease, by Treatment USD Million (2023-2028)
  • Table 279. Italy Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 280. Italy Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 281. Italy Renal Disease, by End User USD Million (2023-2028)
  • Table 282. United Kingdom Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 283. United Kingdom Renal Disease, by Treatment USD Million (2023-2028)
  • Table 284. United Kingdom Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 285. United Kingdom Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 286. United Kingdom Renal Disease, by End User USD Million (2023-2028)
  • Table 287. Netherlands Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 288. Netherlands Renal Disease, by Treatment USD Million (2023-2028)
  • Table 289. Netherlands Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 290. Netherlands Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 291. Netherlands Renal Disease, by End User USD Million (2023-2028)
  • Table 292. Rest of Europe Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 293. Rest of Europe Renal Disease, by Treatment USD Million (2023-2028)
  • Table 294. Rest of Europe Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 295. Rest of Europe Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 296. Rest of Europe Renal Disease, by End User USD Million (2023-2028)
  • Table 297. MEA Renal Disease, by Country USD Million (2023-2028)
  • Table 298. MEA Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 299. MEA Renal Disease, by Treatment USD Million (2023-2028)
  • Table 300. MEA Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 301. MEA Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 302. MEA Renal Disease, by End User USD Million (2023-2028)
  • Table 303. Middle East Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 304. Middle East Renal Disease, by Treatment USD Million (2023-2028)
  • Table 305. Middle East Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 306. Middle East Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 307. Middle East Renal Disease, by End User USD Million (2023-2028)
  • Table 308. Africa Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 309. Africa Renal Disease, by Treatment USD Million (2023-2028)
  • Table 310. Africa Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 311. Africa Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 312. Africa Renal Disease, by End User USD Million (2023-2028)
  • Table 313. North America Renal Disease, by Country USD Million (2023-2028)
  • Table 314. North America Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 315. North America Renal Disease, by Treatment USD Million (2023-2028)
  • Table 316. North America Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 317. North America Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 318. North America Renal Disease, by End User USD Million (2023-2028)
  • Table 319. United States Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 320. United States Renal Disease, by Treatment USD Million (2023-2028)
  • Table 321. United States Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 322. United States Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 323. United States Renal Disease, by End User USD Million (2023-2028)
  • Table 324. Canada Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 325. Canada Renal Disease, by Treatment USD Million (2023-2028)
  • Table 326. Canada Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 327. Canada Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 328. Canada Renal Disease, by End User USD Million (2023-2028)
  • Table 329. Mexico Renal Disease, by Disease Type USD Million (2023-2028)
  • Table 330. Mexico Renal Disease, by Treatment USD Million (2023-2028)
  • Table 331. Mexico Renal Disease, by Distribution Channel USD Million (2023-2028)
  • Table 332. Mexico Renal Disease, by Symptoms USD Million (2023-2028)
  • Table 333. Mexico Renal Disease, by End User USD Million (2023-2028)
  • Table 334. Research Programs/Design for This Report
  • Table 335. Key Data Information from Secondary Sources
  • Table 336. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Renal Disease: by Disease Type USD Million (2017-2022)
  • Figure 5. Global Renal Disease: by Treatment USD Million (2017-2022)
  • Figure 6. Global Renal Disease: by Distribution Channel USD Million (2017-2022)
  • Figure 7. Global Renal Disease: by Symptoms USD Million (2017-2022)
  • Figure 8. Global Renal Disease: by End User USD Million (2017-2022)
  • Figure 9. South America Renal Disease Share (%), by Country
  • Figure 10. Asia Pacific Renal Disease Share (%), by Country
  • Figure 11. Europe Renal Disease Share (%), by Country
  • Figure 12. MEA Renal Disease Share (%), by Country
  • Figure 13. North America Renal Disease Share (%), by Country
  • Figure 14. Global Renal Disease share by Players 2022 (%)
  • Figure 15. Global Renal Disease share by Players (Top 3) 2022(%)
  • Figure 16. Global Renal Disease share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. AM-Pharma (Netherlands) Revenue, Net Income and Gross profit
  • Figure 19. AM-Pharma (Netherlands) Revenue: by Geography 2022
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 22. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 24. Atlentis Therapeutics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Atlentis Therapeutics (Switzerland) Revenue: by Geography 2022
  • Figure 26. Calyxo (United States) Revenue, Net Income and Gross profit
  • Figure 27. Calyxo (United States) Revenue: by Geography 2022
  • Figure 28. Chinook Therapeutics (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Chinook Therapeutics (Canada) Revenue: by Geography 2022
  • Figure 30. CinCor (India) Revenue, Net Income and Gross profit
  • Figure 31. CinCor (India) Revenue: by Geography 2022
  • Figure 32. Early is Good (United States) Revenue, Net Income and Gross profit
  • Figure 33. Early is Good (United States) Revenue: by Geography 2022
  • Figure 34. Federation Bio (United States) Revenue, Net Income and Gross profit
  • Figure 35. Federation Bio (United States) Revenue: by Geography 2022
  • Figure 36. Renalytix (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Renalytix (United Kingdom) Revenue: by Geography 2022
  • Figure 38. Frenova Renal Research (United States) Revenue, Net Income and Gross profit
  • Figure 39. Frenova Renal Research (United States) Revenue: by Geography 2022
  • Figure 40. Goldfinch Bio (Cambridge) Revenue, Net Income and Gross profit
  • Figure 41. Goldfinch Bio (Cambridge) Revenue: by Geography 2022
  • Figure 42. Kibow Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 43. Kibow Biotech (United States) Revenue: by Geography 2022
  • Figure 44. Liminal BioSciences (Canada) Revenue, Net Income and Gross profit
  • Figure 45. Liminal BioSciences (Canada) Revenue: by Geography 2022
  • Figure 46. Renalytix (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 47. Renalytix (United Kingdom) Revenue: by Geography 2022
  • Figure 48. Global Renal Disease: by Disease Type USD Million (2023-2028)
  • Figure 49. Global Renal Disease: by Treatment USD Million (2023-2028)
  • Figure 50. Global Renal Disease: by Distribution Channel USD Million (2023-2028)
  • Figure 51. Global Renal Disease: by Symptoms USD Million (2023-2028)
  • Figure 52. Global Renal Disease: by End User USD Million (2023-2028)
  • Figure 53. South America Renal Disease Share (%), by Country
  • Figure 54. Asia Pacific Renal Disease Share (%), by Country
  • Figure 55. Europe Renal Disease Share (%), by Country
  • Figure 56. MEA Renal Disease Share (%), by Country
  • Figure 57. North America Renal Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AM-Pharma (Netherlands)
  • Pfizer Inc. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Atlentis Therapeutics (Switzerland)
  • Calyxo (United States)
  • Chinook Therapeutics (Canada)
  • CinCor (India)
  • Early is Good (United States)
  • Federation Bio (United States)
  • Renalytix (United Kingdom)
  • Frenova Renal Research (United States)
  • Goldfinch Bio (Cambridge)
  • Kibow Biotech (United States)
  • Liminal BioSciences (Canada)
  • Renalytix (United Kingdom)
Additional players considered in the study are as follows:
The Rogosin Institute (United States) , Vera Therapeutics (United States) , ProKidney (United States) , Osprey Medical (United States)
Select User Access Type

Key Highlights of Report


Apr 2023 224 Pages 89 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Renal Disease research Quantitative research analysis
Global Renal Disease research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Renal Disease market are AM-Pharma (Netherlands), Pfizer Inc. (United States), GlaxoSmithKline (United Kingdom), Atlentis Therapeutics (Switzerland), Calyxo (United States), Chinook Therapeutics (Canada), CinCor (India), Early is Good (United States), Federation Bio (United States), Renalytix (United Kingdom), Frenova Renal Research (United States), Goldfinch Bio (Cambridge), Kibow Biotech (United States), Liminal BioSciences (Canada) and Renalytix (United Kingdom), to name a few.
"Rising Government Support for the Quality Generic Medicines." is seen as one of major influencing trends for Renal Disease Market during projected period 2022-2028.

Know More About Global Renal Disease research Report?

Have a Query? Click Here

Other Related Reports

Hormone Replacement Therapy Comprehensive Study by Type (Estrogen replacement therapy, Growth hormone replacement therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therap...
$ 3350
Panic Attack Treatment Comprehensive Study by Type (Spontaneous Panic Attacks, Situationally Bound Panic Attacks, Situationally Predisposed Panic Attacks), End Users (Adults, Children and Adolescents...
$ 3500
Hirsutism-Treatment Comprehensive Study by Type (Idiopathic Hirsutism, Secondary Hirsutism, Others), Application (Hospitals and Clinics, Medical Research Laboratories, Academic Institutes), Treatment...
$ 3750
Skin Infection Comprehensive Study by Type (Bacterial Skin Infection, Viral Skin Infection, Fungal Skin Infection, Parasitic Skin Infection), by Treatment Type (Traditional Treatment, Basic Treatmen...
$ 3750
Wrist Joint Comprehensive Study by Type (Joint Replacement, Joint Repairment), End -users (Hospital, Clinic, Other), Joint (Ulnocarpal Joint, Radiocarpal Joint, Distal radioulnar Joint) Players and R...
$ 3500
Influenza Vaccines Comprehensive Study by Type (Paediatrics, Adolescence, Adults, Elderly), Application (Hospitals, Clinics, Others), Technology (Egg Based, Cell Culture, Recombinant), Vaccines (Fluz...
$ 3350